Tweet
Vaccine. 2011 Jun 20. [Epub ahead of print]
Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients.
Cotte L, Voirin N, Richard C, Brochier C, Schlienger I, Lack P, Lina B, Vanhems P, Zoulim F.
Source
Hospices Civils de Lyon, H?pital de l'H?tel-Dieu, Service d'H?patologie, 1 place de l'H?pital, 69002 Lyon, France; INSERM Unit 871, Molecular Pathobiology and New Treatments of Viral Hepatitis, 151 Cours Albert Thomas, 69003 Lyon, France.
Abstract
BACKGROUND:
A mass influenza A/H1N1 vaccination campaign took place in France during the 2009 winter. Overall, 7.9% of the general population was vaccinated. However, vaccine coverage data are missing for at-risk groups.
METHODS:
A vaccination centre was implemented for HIV-infected patients followed-up in a French University Hospital. Demographical, clinical and biological characteristics were collected. Adjusted odds ratios (aOR) were calculated to identify factors associated with being vaccinated against A/H1N1 influenza.
RESULTS:
A/H1N1 vaccine coverage was 44.4% (635/1430) in HIV-infected patients. In univariate analysis, uptake of vaccination was significantly associated with male gender, men who have sex with men, age≥50years, ≥1 seasonal influenza risk factor, longer HIV disease, longer duration of antiretroviral therapy, greater number of lines of antiretroviral treatments, lower nadir CD4, recent HIV-RNA<50copies/ml, previous pneumococcal vaccination, >2 visits to the unit during the study period and follow-up by a physician who assessed ≥100patients/year (senior physician). CDC stage, recent CD4 count, diabetes, BMI>30 and pregnancy were not associated with vaccination. After multivariate analysis, vaccination remained significantly associated with age ≥50years (aOR 1.56, CI 1.16-2.09), time since HIV diagnosis (aOR per 1year 1.02, CI 1.00-1.04), previous pneumococcal vaccination (aOR 2.56, CI 1.96-3.34), >2 visits to the unit (aOR 5.09, CI 3.87-6.68) and follow-up by a senior physician (aOR 1.73, CI 1.20-2.48).
CONCLUSION:
A/H1N1 vaccination was more successful in HIV-infected patients than in the French general population. Organization of the vaccination in a convenient location and implication of the physicians seem to be determining factors for A/H1N1 acceptability in this population.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
21699948
[PubMed - as supplied by publisher]
Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients.
Cotte L, Voirin N, Richard C, Brochier C, Schlienger I, Lack P, Lina B, Vanhems P, Zoulim F.
Source
Hospices Civils de Lyon, H?pital de l'H?tel-Dieu, Service d'H?patologie, 1 place de l'H?pital, 69002 Lyon, France; INSERM Unit 871, Molecular Pathobiology and New Treatments of Viral Hepatitis, 151 Cours Albert Thomas, 69003 Lyon, France.
Abstract
BACKGROUND:
A mass influenza A/H1N1 vaccination campaign took place in France during the 2009 winter. Overall, 7.9% of the general population was vaccinated. However, vaccine coverage data are missing for at-risk groups.
METHODS:
A vaccination centre was implemented for HIV-infected patients followed-up in a French University Hospital. Demographical, clinical and biological characteristics were collected. Adjusted odds ratios (aOR) were calculated to identify factors associated with being vaccinated against A/H1N1 influenza.
RESULTS:
A/H1N1 vaccine coverage was 44.4% (635/1430) in HIV-infected patients. In univariate analysis, uptake of vaccination was significantly associated with male gender, men who have sex with men, age≥50years, ≥1 seasonal influenza risk factor, longer HIV disease, longer duration of antiretroviral therapy, greater number of lines of antiretroviral treatments, lower nadir CD4, recent HIV-RNA<50copies/ml, previous pneumococcal vaccination, >2 visits to the unit during the study period and follow-up by a physician who assessed ≥100patients/year (senior physician). CDC stage, recent CD4 count, diabetes, BMI>30 and pregnancy were not associated with vaccination. After multivariate analysis, vaccination remained significantly associated with age ≥50years (aOR 1.56, CI 1.16-2.09), time since HIV diagnosis (aOR per 1year 1.02, CI 1.00-1.04), previous pneumococcal vaccination (aOR 2.56, CI 1.96-3.34), >2 visits to the unit (aOR 5.09, CI 3.87-6.68) and follow-up by a senior physician (aOR 1.73, CI 1.20-2.48).
CONCLUSION:
A/H1N1 vaccination was more successful in HIV-infected patients than in the French general population. Organization of the vaccination in a convenient location and implication of the physicians seem to be determining factors for A/H1N1 acceptability in this population.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
21699948
[PubMed - as supplied by publisher]
